<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-21247" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Epinastine</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Jha</surname>
            <given-names>Mawra</given-names>
          </name>
          <aff>Sharda University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Moshirfar</surname>
            <given-names>Majid</given-names>
          </name>
          <aff>University of Utah/John Moran Eye Center; Hoopes Vision/HDR Research Center; Utah Lions Eye Bank</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Mawra Jha declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Majid Moshirfar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>18</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-21247.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Epinastine is a medication used in the treatment and management of allergic conjunctivitis. This activity reviews the indications, contraindications, activity, adverse events, and other key elements of epinastine therapy in the clinical setting related to the essential points needed by members of an interprofessional team managing the care of patients with allergic reactions conjunctivitis and its related conditions and sequelae.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of epinastine.</p></list-item><list-item><p>Describe the potential adverse effects of epinastine.</p></list-item><list-item><p>Review the appropriate monitoring for patients receiving therapy with epinastine.</p></list-item><list-item><p>Outline interprofessional team strategies for improving care coordination and communication to advance epinastine and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21247&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21247">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-21247.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Epinastine belongs to the class of second-generation antihistamines and is also a mast cell stabilizer. It also shows anti-leukotriene, anti-PAF, and anti-bradykinin activities, which provide additional anti-allergic activities. Antihistamines and mast cell stabilizers have been used to manage various allergic conditions for many years.</p>
        <p>Currently, epinastine is FDA approved to treat:</p>
        <p>Allergic conjunctivitis - Allergic conjunctivitis is an umbrella term that includes<xref ref-type="bibr" rid="article-21247.r1">[1]</xref><xref ref-type="bibr" rid="article-21247.r2">[2]</xref>:</p>
        <list list-type="order">
          <list-item>
            <p>Perennial allergic conjunctivitis (PAC)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Seasonal allergic conjunctivitis (SAC)</p>
          </list-item>
          <list-item>
            <p>Vernal keratoconjunctivitis (VKC)&#x000a0;</p>
          </list-item>
          <list-item>
            <p>Atopic keratoconjunctivitis (AKC)&#x000a0;</p>
          </list-item>
        </list>
        <p>Epinastine is used in many countries to treat the following conditions as well:</p>
        <list list-type="bullet">
          <list-item>
            <p>Chronic urticaria<xref ref-type="bibr" rid="article-21247.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Psoriasis vulgaris<xref ref-type="bibr" rid="article-21247.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Allergic Rhinitis<xref ref-type="bibr" rid="article-21247.r3">[3]</xref></p>
          </list-item>
          <list-item>
            <p>Atopic Dermatitis<xref ref-type="bibr" rid="article-21247.r4">[4]</xref></p>
          </list-item>
        </list>
        <p>The chemical structure of epinastine is a benzazepine, which is 6,11-dihydro-5H-dibenzo[b,e]azepine in which the azepine ring merges with the side of 4,5-dihydro-1H-imidazole-2-amine. It is a member of benzazepine and guanidines. It is solid at room temperature, and the melting point is 205&#x000a0;to 208 degrees Celsius.</p>
      </sec>
      <sec id="article-21247.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Epinastine acts through various pathways to decrease inflammation. It acts as:</p>
        <list list-type="order">
          <list-item>
            <p>a) Mast cell stabilizer:-Mast cells, when activated, promote IgE mediated allergic reactions. Epinastine causes the cessation of degranulation of mast cells by stabilizing them to reduce inflammation.<xref ref-type="bibr" rid="article-21247.r1">[1]</xref>&#x000a0;Mast cell stabilizers act via altering the outcome of delayed chloride channels in the cellular membrane, which is essential for the degranulation of mast cells.</p>
          </list-item>
        </list>
        <list list-type="order">
          <list-item>
            <p>b) Anti-histamine:-Inflammatory conditions have been very well known to be associated with the activation of histamine receptors. Histamine is known to increase the permeability of the vessels, as a result of which fluid exudates into the interstitial space. The vascular phase is followed by the cellular phase and sets of an inflammatory cascade. Drugs that block the effects of histamine by competitively inhibiting histamine at its receptors or behaving as inverse agonists are known as anti-histamines. It prevents the binding of histamine to H1 and H2 receptors.<xref ref-type="bibr" rid="article-21247.r5">[5]</xref></p>
          </list-item>
        </list>
        <p>&#x000a0;c) It ceases the release of pro-inflammatory mediators, and hence inflammatory response does not progress.</p>
      </sec>
      <sec id="article-21247.s4" sec-type="Administration">
        <title>Administration</title>
        <p>The drug is available as epinastine hydrochloride eye drops, as oral epinastine tablets, and in the form of syrup for the management of various diseases.</p>
        <p>
<bold>Eye Drops</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Epinastine has shown superiority to placebo in the management of various manifestations of allergic conjunctivitis. It is used topically as eye drops for allergic conjunctivitis.</p>
          </list-item>
          <list-item>
            <p>Topical mast cell stabilizers and antihistamines are effective in providing relief in allergic conjunctivitis without any systemic absorption. Patients can use it throughout the allergy season. It shows the onset of action within 3 minutes, and the action lasts for over 8 hours.<xref ref-type="bibr" rid="article-21247.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>It can be used as one drop in each eye twice daily.<xref ref-type="bibr" rid="article-21247.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>In the USA, only topical ophthalmic drops are an approved dose form.</p>
          </list-item>
        </list>
        <p>
<bold>Oral&#x000a0;Dosing</bold>
</p>
        <p>Tablets</p>
        <list list-type="bullet">
          <list-item>
            <p>Clinicians can prescribe this drug for patients with allergic conditions in the form of oral tablets at a dose of 10 to 20 mg once daily.<xref ref-type="bibr" rid="article-21247.r8">[8]</xref></p>
          </list-item>
        </list>
        <p>Syrup</p>
        <list list-type="bullet">
          <list-item>
            <p>Epinastine is also available in the form of syrup for the pediatric age group. The clinician should adjust dosing for pediatric patients.<xref ref-type="bibr" rid="article-21247.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-21247.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Epinastine is a safe and well-tolerated drug. It is used topically as an eye drop, and it does not cause any systemic side effects.<xref ref-type="bibr" rid="article-21247.r9">[9]</xref> However, it can cause a burning sensation in the eyes, hyperemia, increased lacrimation, folliculitis, and pruritus.</p>
        <p>It is unable to cross the blood-brain barrier, and hence it doesn&#x02019;t cause any adverse effects related to the central nervous system. There is no diffusion at the central nervous system because of its polarity and cationic charge at the ph of the physiological state.<xref ref-type="bibr" rid="article-21247.r10">[10]</xref>&#x000a0;It has no cardiotoxic effects.<xref ref-type="bibr" rid="article-21247.r3">[3]</xref></p>
        <p>Epinastine is not teratogenic, even at high doses in the animal model<xref ref-type="bibr" rid="article-21247.r3">[3]</xref>. However, there is not enough data from human clinical trials, and hence, it should be used in pregnancy only if the use justifies the benefit compared to the potential risk.</p>
      </sec>
      <sec id="article-21247.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Epinastine is contraindicated in patients who have allergy/sensitivity to epinastine. Epinastine should be administered only after a test dose.</p>
        <p>Use in specific cases:</p>
        <list list-type="bullet">
          <list-item>
            <p>Pregnancy&#x000a0;</p>
          </list-item>
        </list>
        <p>Epinastine is a pregnancy category C drug. However, it should be used in pregnant patients judiciously.</p>
        <list list-type="bullet">
          <list-item>
            <p>Breastfeeding Mothers</p>
          </list-item>
        </list>
        <p>Studies have shown that epinastine gets transferred into breastmilk, but the resulting infant serum levels are minimal. Nonetheless, breastfeeding mothers must consult a physician before administering epinastine.</p>
        <list list-type="bullet">
          <list-item>
            <p>Pediatric Population</p>
          </list-item>
        </list>
        <p>The safety of the drug has not been established in patients below two years of age. The medication should have the dose adjusted according to the patient's body weight in the pediatric age group above two years.</p>
        <list list-type="bullet">
          <list-item>
            <p>Geriatric Population&#x000a0;</p>
          </list-item>
        </list>
        <p>No such difference in the dose has been reported for geriatric patients. However, the clinician should obtain thorough liver function and kidney function tests before prescribing epinastine.</p>
      </sec>
      <sec id="article-21247.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>
<bold>Pharmacokinetic</bold>
</p>
        <p>Epinastine is a powerful anti-allergic drug that has antihistaminic properties. In addition to that, epinastine also shows anti leukotriene, anti-PAF, and anti-bradykinin activities, which provide additional anti-allergic activities.<xref ref-type="bibr" rid="article-21247.r3">[3]</xref></p>
        <p>Plasma concentration at steady state is approximately 5.96&#x000a0;to 6.04 ng/ml.<xref ref-type="bibr" rid="article-21247.r10">[10]</xref></p>
        <p>Epinastine is categorized as a second-generation antihistamine as it can not cross the blood-brain barrier. There is no diffusion at the central nervous system because of its polarity and cationic charge at the ph of the physiological state. Since it doesn&#x02019;t cross the blood-brain barrier, it has no CNS effects and does not cause sedation in patients.</p>
        <p>The duration of onset of epinastine is approximately 180 seconds and lasts for about 8 hours when administered as an eye drop.</p>
        <p>
<bold>Monitoring</bold>
</p>
        <p>Physicians should educate the patients about the course of therapy, potential adverse/side effects, and steps to take in case of an adverse event. Patients should be monitored via regular checkups to assess the relief in their symptoms. Patient compliance with the prescription should be ensured and encouraged. Drug dose should be adjusted as needed based on regular checkups and thorough examination.&#x000a0;</p>
      </sec>
      <sec id="article-21247.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>There are no reported cases of overdose with epinastine to date. However, in case of an overdose, the institution and health care providers must act promptly to ensure airway patency and that there is no circulatory collapse.&#x000a0;</p>
      </sec>
      <sec id="article-21247.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Anti-histamines have been the mainstay for the treatment of allergic conditions. Epinastine is a mast cell stabilizer as well as an anti-histaminic, which the FDA has approved for topical use to relieve various allergic conditions. Since epinastine does not possess any CNS toxicity, it is superior to other anti-histamines with sedative properties. An accurate diagnosis is necessary before prescribing epinastine. Any clinician can prescribe epinastine, and the patient must be monitored regularly for adverse outcomes. Patients should be encouraged to follow the treatment plan; this requires an interprofessional team effort from the clinicians (including specialists, NPs, PAs, and optometrists), nursing staff, and pharmacists, coordinating efforts and communicating across interprofessional lines to improve and enhance patient care outcomes. [Level 5]</p>
      </sec>
      <sec id="article-21247.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=21247&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=21247">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/21247/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=21247">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-21247.s11">
        <title>References</title>
        <ref id="article-21247.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ben-Eli</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Solomon</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Topical antihistamines, mast cell stabilizers, and dual-action agents in ocular allergy: current trends.</article-title>
            <source>Curr Opin Allergy Clin Immunol</source>
            <year>2018</year>
            <month>Oct</month>
            <volume>18</volume>
            <issue>5</issue>
            <fpage>411</fpage>
            <page-range>411-416</page-range>
            <pub-id pub-id-type="pmid">30020258</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21247.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>La Rosa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lionetti</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Reibaldi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Russo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Longo</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Leonardi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Tomarchio</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Avitabile</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Reibaldi</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Allergic conjunctivitis: a comprehensive review of the literature.</article-title>
            <source>Ital J Pediatr</source>
            <year>2013</year>
            <month>Mar</month>
            <day>14</day>
            <volume>39</volume>
            <fpage>18</fpage>
            <pub-id pub-id-type="pmid">23497516</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21247.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tasaka</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Epinastine: An update of its pharmacology, metabolism, clinical efficacy and tolerability in the treatment of allergic diseases.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2000</year>
            <month>Nov</month>
            <volume>36</volume>
            <issue>11</issue>
            <fpage>735</fpage>
            <page-range>735-57</page-range>
            <pub-id pub-id-type="pmid">12845334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21247.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fraunfelder</surname>
                <given-names>FW</given-names>
              </name>
            </person-group>
            <article-title>Epinastine hydrochloride for atopic disease.</article-title>
            <source>Drugs Today (Barc)</source>
            <year>2004</year>
            <month>Aug</month>
            <volume>40</volume>
            <issue>8</issue>
            <fpage>677</fpage>
            <page-range>677-83</page-range>
            <pub-id pub-id-type="pmid">15510239</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21247.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maciel-Guerra</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Penha</surname>
                <given-names>M&#x000c1;</given-names>
              </name>
              <name>
                <surname>Jorge</surname>
                <given-names>MFS</given-names>
              </name>
              <name>
                <surname>Lib&#x000f3;rio</surname>
                <given-names>RDS</given-names>
              </name>
              <name>
                <surname>Carrijo</surname>
                <given-names>ACNDA</given-names>
              </name>
              <name>
                <surname>Parise-Fortes</surname>
                <given-names>MR</given-names>
              </name>
              <name>
                <surname>Miot</surname>
                <given-names>HA</given-names>
              </name>
            </person-group>
            <article-title>Suppression of wheal and flare in histamine test by the main H1 antihistamines commercialized in Brazil.</article-title>
            <source>An Bras Dermatol</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>93</volume>
            <issue>2</issue>
            <fpage>233</fpage>
            <page-range>233-237</page-range>
            <pub-id pub-id-type="pmid">29723372</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21247.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Friedlaender</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Epinastine in the management of ocular allergic disease.</article-title>
            <source>Int Ophthalmol Clin</source>
            <year>2006</year>
            <season>Fall</season>
            <volume>46</volume>
            <issue>4</issue>
            <fpage>85</fpage>
            <page-range>85-6</page-range>
            <pub-id pub-id-type="pmid">17060794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21247.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Whitcup</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Bradford</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lue</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Schiffman</surname>
                <given-names>RM</given-names>
              </name>
              <name>
                <surname>Abelson</surname>
                <given-names>MB</given-names>
              </name>
            </person-group>
            <article-title>Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.</article-title>
            <source>Clin Ther</source>
            <year>2004</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>29</fpage>
            <page-range>29-34</page-range>
            <pub-id pub-id-type="pmid">14996515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21247.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sarashina</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Tatami</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamamura</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Tsuda</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Igarashi</surname>
                <given-names>T</given-names>
              </name>
            </person-group>
            <article-title>Population pharmacokinetics of epinastine, a histamine H1 receptor antagonist, in adults and children.</article-title>
            <source>Br J Clin Pharmacol</source>
            <year>2005</year>
            <month>Jan</month>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>43</fpage>
            <page-range>43-53</page-range>
            <pub-id pub-id-type="pmid">15606439</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21247.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Pradhan</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Abhishek</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Mah</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Epinastine: topical ophthalmic second generation antihistamine without significant systemic side effects.</article-title>
            <source>Expert Opin Drug Metab Toxicol</source>
            <year>2009</year>
            <month>Sep</month>
            <volume>5</volume>
            <issue>9</issue>
            <fpage>1135</fpage>
            <page-range>1135-40</page-range>
            <pub-id pub-id-type="pmid">19630694</pub-id>
          </element-citation>
        </ref>
        <ref id="article-21247.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jeong</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Jang</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Cho</surname>
                <given-names>HY</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>YB</given-names>
              </name>
            </person-group>
            <article-title>Pharmacokinetic Comparison of Epinastine Using Developed Human Plasma Assays.</article-title>
            <source>Molecules</source>
            <year>2020</year>
            <month>Jan</month>
            <day>03</day>
            <volume>25</volume>
            <issue>1</issue>
            <pub-id pub-id-type="pmid">31947890</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
